Rexahn Pharmaceuticals Inc. (NYSE American:RNN) is a clinical stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of cancer. The company's mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn's product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Preclinical studies show that certain of Rexahn's product candidates may be effective against multiple types of cancer, including drug resistant cancers, and difficult-to-treat cancers, and others may augment the effectiveness of current FDA-approved cancer treatments. The company has two oncology product candidates, RX-3117 and RX-5902, in Phase 2 clinical development and additional compounds in preclinical development including RX-0201. For more information about the Company and its oncology programs, please visit www.rexahn.com.
View Top Employees from Rexahn PharmaceuticalsWebsite | http://www.rexahn.com |
Ticker | RNN |
Revenue | $369000 |
Employees | 8 (8 on RocketReach) |
Founded | 2001 |
Address | 15245 Shady Grove Rd Suite 455, Rockville, Maryland 20850, US |
Phone | (240) 268-5300 |
Fax | (240) 268-5310 |
Technologies |
JavaScript,
HTML,
PHP
+21 more
(view full list)
|
Industry | Pharmaceuticals, Pharmaceutical Manufacturing, Drug Manufacturing & Research, Biotechnology, Drug Discovery, Science and Engineering, Oncology, Healthcare, Medical Device, Clinical Development, Health Care, Pharmaceutical |
Web Rank | 3 Million |
Keywords | Rnn Ir, Rexahn Pharmaceuticals, Rexhan, A Phase 1, Open-Label, Dose-Ranging, Safety And Pharmacokinetic Study To Determine The Maximum Tolerated Dose Of Rx-3117 Administered Orally As A Single-Agent To Subjects With Advanced Malignancies, Rx-3117 |
Competitors | BIONOMICS LIMITED, Minerva Neurosciences, Quince Therapeutics, Soligenix, Inc., Trevena Inc |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular Rexahn Pharmaceuticals employee's phone or email?
The Rexahn Pharmaceuticals annual revenue was $369000 in 2024.
8 people are employed at Rexahn Pharmaceuticals.
Rexahn Pharmaceuticals is based in Rockville, Maryland.
The NAICS codes for Rexahn Pharmaceuticals are [32541, 32, 3254, 325].
The SIC codes for Rexahn Pharmaceuticals are [28, 283].